Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
RenovoRx Inc (RNXT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.31+1.55%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RNXT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stable and effective management team | A supporting condition in RenovoRx Inc's published investment case. The stated target is No major leadership departures or disruptions in next 4 quarters. | Intact | Key executives leave or management turmoil worsens | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, not an established compounder: revenue and customer adoption are growing from a small base, while the business remains loss-making. The long-term thesis is in a watch state, with medium confidence and a higher risk label than before.
The valuation is expensive versus peers, with a 3.38 premium, and the model has low confidence. The evidence points to optionality as the main reason for the gap, but does not specify exactly what growth expectations the market assumes.
Near term, execution is progressing: second-quarter revenue rose 61% sequentially, guidance was raised, and active commercial cancer centers increased from 16 to 21. Management is also on track with trial enrollment, though completion is expected in the first half of 2027 and topline data in the second half; losses and high risk remain, and the next-results miss probability is flagged at 47%.
The multi-year thesis depends on continued revenue growth, expansion toward 36 active commercial centers by year-end 2026, and progress through the TIGeR-PaC trial. A reversal and guidance cut would damage credibility, while weakening jobs data could weigh on healthcare names; continued strong results and guidance from sector peers could support sector momentum.
Over the next 1 to 3 years, RNXT’s case rests on turning early commercial adoption and trial progress into sustained growth, against a backdrop of losses, high risk, and an expensive valuation versus peers. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management is focused on fixing Nasdaq listing issues. |
| Under Pressure |
| Nasdaq delisting occurs or deficiency not resolved by end 2026 |
Bid $1.31 vs $1.00 target; deficiency unresolved July 2026 Nasdaq delisting notice for minimum bid deficiency; current price $1.31. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to $3-4 million in 2026 | A primary condition in RenovoRx Inc's published investment case. The stated target is 3.5 million USD. | Intact | Revenue falls below $3 million in 2026 | Revenue: $909,000 FY2026-Q2; GAAP. Published target: 3.5 million USD. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026909,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.14 → $-0.14 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-07-25 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-07-26 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-07-27 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-07-28 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-07-29 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-07-30 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-07-31 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-01 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-02 | $-0.15 | $12,292,250 | 2 / 4 |
| 2026-08-03 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-04 | $-0.15 | $12,292,250 | 2 / 4 |
| 2026-08-05 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-06 | $-0.15 | $12,292,250 | 2 / 4 |
| 2026-08-08 | $-0.15 | $12,292,250 | 2 / 4 |
| 2026-08-09 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-10 | $-0.15 | $12,292,250 | 2 / 4 |
| 2026-08-12 | $-0.15 | $12,292,250 | 2 / 4 |
| 2026-08-13 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-14 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-15 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-16 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-17 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-18 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-19 | $-0.14 | $12,292,250 | 2 / 3 |
| 2026-08-20 | $-0.16 | $10,056,000 | 2 / 3 |
| 2026-08-21 | $-0.16 | $10,058,750 | 2 / 3 |
| 2026-08-22 | $-0.16 | $10,058,750 | 2 / 3 |
| 2026-08-23 | $-0.16 | $10,058,750 | 2 / 3 |
| 2026-08-24 | $-0.16 | $10,058,750 | 2 / 3 |
| 2026-08-25 | $-0.16 | $10,058,750 | 2 / 3 |
| 2026-08-26 | $-0.16 | $10,058,750 | 2 / 3 |
| 2026-08-27 | $-0.16 | $10,058,750 | 2 / 3 |
| 2026-08-28 | $-0.16 | $10,058,750 | 2 / 3 |
| 2026-08-29 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-08-30 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-08-31 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-01 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-02 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-03 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-04 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-05 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-06 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-07 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-08 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-09 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-10 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-11 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-12 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-13 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-14 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-15 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-16 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-17 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-18 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-19 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-20 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-21 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-22 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-23 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-24 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-25 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-26 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-27 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-28 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-29 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-09-30 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-01 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-02 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-03 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-04 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-05 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-06 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-07 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-08 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-09 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-10 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-11 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-12 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-13 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-14 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-15 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-16 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-17 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-18 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-19 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-20 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-21 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-22 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-23 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-24 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-25 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-26 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-27 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-28 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-29 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-30 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-10-31 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-11-01 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-11-02 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-11-03 | $-0.14 | $11,508,750 | 2 / 3 |
| 2026-11-04 | $-0.14 | $11,508,750 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.